The efficacy, safety, cost-effectiveness and mechanism of action of the anti-TNF antibody infliximab in patients with AP is tested and potential safety signals will be adverse events related to infliximab.
Juan Lin, M. Smyth, C. Spowart et al.· BMJ Open· 0 citations
BACKGROUND
Therapeutic options for inflammatory bowel disease (IBD) have expanded rapidly with the introduction of selective interleukin (IL)-23 inhibitors, Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators, and several emerging therapeutic classes. Consequently, the major clinical challenge has shif...
Despite significant advances in understanding the biology of inflammatory bowel diseases (IBD), the underlying etiology is still unknown, and currently available treatment options are not curative. Furthermore, even after the advent of multiple targeted “advanced” therapies, approximately one-third of patients do not r...
Samuel Majna, B. Brezina, M. Sharip et al.· Journal of Personalized Medi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
